Your session is about to expire
← Back to Search
Caspase-1 Inhibitor
Belnacasan for Coronavirus
Phase 2
Waitlist Available
Led By Glenn Wortmann, MD
Research Sponsored by MedStar Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 4, 7, 10, 14, 21, 28, 42, 60 post randomization
Awards & highlights
Summary
This trial tests a pill called Belnacasan for patients with mild to moderate COVID-19. The pill aims to reduce harmful inflammation by blocking an enzyme that can cause the immune system to overreact and damage organs.
Eligible Conditions
- Coronavirus
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ days 4, 7, 10, 14, 21, 28, 42, 60 post randomization
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 4, 7, 10, 14, 21, 28, 42, 60 post randomization
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Safety and Tolerability of Belnacasan
Secondary study objectives
Changes on the WHO 9-Point Ordinal Scale
Perinatal death
Experiences of normal surrogate markers of COVID-19-related inflammation and organ involvement
+12 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: InterventionalExperimental Treatment1 Intervention
900mg dose TID Administration Total: 2700mg
Group II: PlaceboPlacebo Group1 Intervention
900mg dose TID Administration Total: 2700mg
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Belnacasan
2021
Completed Phase 2
~50
Find a Location
Who is running the clinical trial?
MedStar HealthLead Sponsor
4 Previous Clinical Trials
70,398 Total Patients Enrolled
Glenn Wortmann, MDPrincipal InvestigatorMedStar Health
1 Previous Clinical Trials
414 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger